VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q42773137  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000200.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q42773137‏
024 ‎‡a  0000-0001-5420-5704‏ ‎‡2  orcid‏
024 ‎‡a  56005654300‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q42773137‏
100 0 ‎‡a  Jin Wang‏ ‎‡9  ast‏ ‎‡9  nl‏ ‎‡9  es‏ ‎‡9  sl‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  Jin Wang‏ ‎‡c  Pharmacology researcher ORCID: 0000-0001-5420-5704‏ ‎‡9  en‏
670 ‎‡a  Author's 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo‏
670 ‎‡a  Author's Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength‏
670 ‎‡a  Author's Design, synthesis, and biological action of 20R-hydroxyvitamin D3.‏
670 ‎‡a  Author's Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents‏
670 ‎‡a  Author's Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties‏
670 ‎‡a  Author's Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties‏
670 ‎‡a  Author's Discovery of novel 2-aryl-4-benzoyl-imidazole‏
670 ‎‡a  Author's Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents‏
670 ‎‡a  Author's Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors‏
670 ‎‡a  Author's In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland.‏
670 ‎‡a  Author's New substituted 4H-chromenes as anticancer agents‏
670 ‎‡a  Author's Novel activities of CYP11A1 and their potential physiological significance.‏
670 ‎‡a  Author's Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis‏
670 ‎‡a  Author's RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D.‏
670 ‎‡a  Author's Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents‏
670 ‎‡a  Author's Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.‏
670 ‎‡a  Author's Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization‏
909 ‎‡a  (scopus) 56005654300‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000154205704‏ ‎‡9  1‏
919 ‎‡a  discoveryofnovel2mitochondriaderivedactivatorofcaspasemimeticsasselectiveinhibitorofapoptosisproteininhibitors‏ ‎‡A  Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors‏ ‎‡9  1‏
919 ‎‡a  discoveryofnovel2aryl4benzoylimidazoleabi3analoguestargetingtubulinpolymerizationasantiproliferativeagents‏ ‎‡A  Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents‏ ‎‡9  1‏
919 ‎‡a  discoveryof4aryl2benzoylimidazolesastubulinpolymerizationinhibitorwithpotentantiproliferativeproperties‏ ‎‡A  Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties‏ ‎‡9  1‏
919 ‎‡a  designsynthesisandstructureactivityrelationshipstudiesofnovelsurvivininhibitorswithpotentantiproliferativeproperties‏ ‎‡A  Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties‏ ‎‡9  1‏
919 ‎‡a  designsynthesisandbiologicalevaluationofstablecolchicinebindingsitetubulininhibitorsaspotentialanticanceragents‏ ‎‡A  Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents‏ ‎‡9  1‏
919 ‎‡a  designsynthesisandbiologicalactionof20rhydroxyvitamind3‏ ‎‡A  Design, synthesis, and biological action of 20R-hydroxyvitamin D3.‏ ‎‡9  1‏
919 ‎‡a  correlationbetweensecosteroidinducedvitamin500receptoractivityinmelanomacellsandcomputermodeledreceptorbindingstrength‏ ‎‡A  Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength‏ ‎‡9  1‏
919 ‎‡a  20shydroxyvitamind3noncalcemicproductofcyp11a1actiononvitamind3exhibitspotentantifibrogenicactivityinvivo‏ ‎‡A  20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo‏ ‎‡9  1‏
919 ‎‡a  discoveryofnovel2aryl4benzoylimidazole‏ ‎‡A  Discovery of novel 2-aryl-4-benzoyl-imidazole‏ ‎‡9  1‏
919 ‎‡a  synthesisandantiproliferativeactivityofnovel2aryl4benzoylimidazolederivativestargetingtubulinpolymerization‏ ‎‡A  Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization‏ ‎‡9  1‏
919 ‎‡a  synergisticcombinationofnoveltubulininhibitorabi274andvemurafenibovercomevemurafenibacquiredresistanceinbrafv600emelanoma‏ ‎‡A  Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.‏ ‎‡9  1‏
919 ‎‡a  structuraloptimizationofindolederivativesactingatcolchicinebindingsiteaspotentialanticanceragents‏ ‎‡A  Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents‏ ‎‡9  1‏
919 ‎‡a  rorαandrorγareexpressedinhumanskinandserveasreceptorsforendogenouslyproducednoncalcemic20hydroxyand2023dihydroxyvitamin500‏ ‎‡A  RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D.‏ ‎‡9  1‏
919 ‎‡a  noveltubulinpolymerizationinhibitorsovercomemultidrugresistanceandreducemelanomalungmetastasis‏ ‎‡A  Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis‏ ‎‡9  1‏
919 ‎‡a  novelactivitiesofcyp11a1andtheirpotentialphysiologicalsignificance‏ ‎‡A  Novel activities of CYP11A1 and their potential physiological significance.‏ ‎‡9  1‏
919 ‎‡a  newsubstituted4hchromenesasanticanceragents‏ ‎‡A  New substituted 4H-chromenes as anticancer agents‏ ‎‡9  1‏
919 ‎‡a  invivoproductionofnovelvitamind2hydroxyderivativesbyhumanplacentasepidermalkeratinocytescaco2coloncellsandtheadrenalgland‏ ‎‡A  In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland.‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  LC|nr 92019148‏
996 ‎‡2  CYT|AC000416687‏
996 ‎‡2  DNB|1307923275‏
996 ‎‡2  ISNI|0000000063358588‏
996 ‎‡2  J9U|987007327082405171‏
996 ‎‡2  BNF|16922422‏
996 ‎‡2  LC|n 80114164‏
996 ‎‡2  ISNI|0000000063822213‏
996 ‎‡2  LC|no2014164496‏
996 ‎‡2  SUDOC|266065341‏
996 ‎‡2  ISNI|0000000051568764‏
996 ‎‡2  DNB|1114184020‏
996 ‎‡2  NTA|140485635‏
996 ‎‡2  LC|n 2003058881‏
996 ‎‡2  LC|n 84190587‏
996 ‎‡2  ISNI|0000000044456916‏
996 ‎‡2  DNB|172442095‏
996 ‎‡2  ISNI|0000000063508187‏
996 ‎‡2  LC|nr 91008296‏
996 ‎‡2  ISNI|0000000044296289‏
996 ‎‡2  DNB|1073190420‏
996 ‎‡2  CYT|AC000642210‏
996 ‎‡2  DNB|1192403746‏
996 ‎‡2  SUDOC|158069013‏
996 ‎‡2  ISNI|0000000053806973‏
996 ‎‡2  BNF|18075284‏
996 ‎‡2  LC|nb2002054342‏
996 ‎‡2  LC|nb2016011507‏
996 ‎‡2  NSK|000164499‏
996 ‎‡2  LC|n 82096404‏
996 ‎‡2  BNF|16744654‏
996 ‎‡2  LC|n 2011063243‏
996 ‎‡2  LC|nr 95006173‏
996 ‎‡2  LC|no2022055036‏
996 ‎‡2  LC|no2022057827‏
996 ‎‡2  BIBSYS|2009457‏
996 ‎‡2  NTA|344697223‏
996 ‎‡2  ISNI|0000000080199742‏
996 ‎‡2  ISNI|0000000041282850‏
996 ‎‡2  LC|n 2018006281‏
996 ‎‡2  CAOONL|ncf11955150‏
996 ‎‡2  ISNI|0000000064226878‏
996 ‎‡2  LC|n 82215159‏
996 ‎‡2  DNB|1328705692‏
996 ‎‡2  ISNI|0000000012441277‏
996 ‎‡2  ISNI|0000000504933761‏
996 ‎‡2  SUDOC|244906335‏
996 ‎‡2  PLWABN|9812389714505606‏
996 ‎‡2  LC|n 83045635‏
996 ‎‡2  ISNI|0000000382753518‏
996 ‎‡2  CAOONL|ncf10569142‏
996 ‎‡2  SUDOC|157432025‏
996 ‎‡2  LC|no2005100119‏
996 ‎‡2  ISNI|0000000368637377‏
996 ‎‡2  CYT|AC000642497‏
996 ‎‡2  SUDOC|197230245‏
996 ‎‡2  ISNI|0000000046801664‏
996 ‎‡2  DNB|142840122‏
996 ‎‡2  DNB|1014983487‏
996 ‎‡2  DNB|1253301298‏
996 ‎‡2  LC|no2010003012‏
996 ‎‡2  LC|n 88648589‏
996 ‎‡2  NUKAT|n 2016072180‏
996 ‎‡2  NII|DA06901506‏
996 ‎‡2  DNB|1331094402‏
996 ‎‡2  PLWABN|9814027747205606‏
996 ‎‡2  NUKAT|n 2020216981‏
996 ‎‡2  ISNI|0000000064088161‏
996 ‎‡2  DNB|1236438477‏
996 ‎‡2  LC|n 2013011938‏
996 ‎‡2  CYT|AC000637037‏
996 ‎‡2  CYT|AC000256200‏
996 ‎‡2  DNB|1140849859‏
996 ‎‡2  SUDOC|136482031‏
996 ‎‡2  LC|n 2020044857‏
996 ‎‡2  DNB|1186743174‏
996 ‎‡2  LC|no 97068660‏
996 ‎‡2  NUKAT|n 2011070920‏
996 ‎‡2  ISNI|000000050156418X‏
996 ‎‡2  ISNI|0000000021758962‏
996 ‎‡2  CYT|AC000210218‏
996 ‎‡2  NSK|000192927‏
996 ‎‡2  ISNI|0000000012463863‏
996 ‎‡2  NUKAT|n 2010045122‏
996 ‎‡2  CYT|AC000658320‏
996 ‎‡2  LC|no2014103651‏
996 ‎‡2  DNB|1267847921‏
996 ‎‡2  BNF|14595956‏
996 ‎‡2  SUDOC|151103658‏
996 ‎‡2  PLWABN|9811563437405606‏
996 ‎‡2  LC|no2011134610‏
996 ‎‡2  LC|nb2014015336‏
996 ‎‡2  DNB|1173634975‏
996 ‎‡2  ISNI|0000000459798088‏
996 ‎‡2  ISNI|0000000498251392‏
996 ‎‡2  NKC|jn20010601056‏
996 ‎‡2  CYT|AC000257428‏
996 ‎‡2  DNB|1074163303‏
996 ‎‡2  BNF|14628807‏
996 ‎‡2  J9U|987007457592305171‏
996 ‎‡2  DNB|1089694849‏
996 ‎‡2  NUKAT|n 2024061634‏
996 ‎‡2  NTA|364154357‏
996 ‎‡2  CYT|AC000649836‏
996 ‎‡2  CYT|AC000655080‏
996 ‎‡2  BNF|14108870‏
996 ‎‡2  DNB|1245800485‏
996 ‎‡2  DNB|1332948103‏
996 ‎‡2  RERO|A003957486‏
996 ‎‡2  PLWABN|9810555406905606‏
996 ‎‡2  RERO|A006158182‏
996 ‎‡2  CYT|AC000633612‏
996 ‎‡2  ISNI|0000000064072506‏
996 ‎‡2  LC|nr 93030428‏
996 ‎‡2  NII|DA09567488‏
996 ‎‡2  ISNI|0000000083359959‏
996 ‎‡2  ISNI|0000000063770177‏
996 ‎‡2  LC|no2001072340‏
996 ‎‡2  SUDOC|122150279‏
996 ‎‡2  DNB|133071138‏
996 ‎‡2  NUKAT|n 2005017357‏
996 ‎‡2  ISNI|0000000502626944‏
996 ‎‡2  DNB|1171259956‏
996 ‎‡2  SUDOC|191472050‏
996 ‎‡2  LC|nr 90007704‏
996 ‎‡2  LC|no2016158311‏
996 ‎‡2  BNF|14570335‏
996 ‎‡2  ISNI|0000000064349827‏
996 ‎‡2  LC|nr 94010273‏
996 ‎‡2  NSK|000574095‏
996 ‎‡2  LC|n 96018218‏
996 ‎‡2  LC|n 82142616‏
996 ‎‡2  DNB|126612134X‏
996 ‎‡2  RERO|A000175004‏
996 ‎‡2  PLWABN|9811781231405606‏
996 ‎‡2  RERO|A000175006‏
996 ‎‡2  DNB|1069499633‏
996 ‎‡2  LC|no2022117089‏
996 ‎‡2  SUDOC|26242875X‏
996 ‎‡2  ISNI|0000000064250480‏
996 ‎‡2  ISNI|0000000381615746‏
996 ‎‡2  SIMACOB|138475875‏
996 ‎‡2  ISNI|0000000033673077‏
996 ‎‡2  CYT|AC000662846‏
996 ‎‡2  J9U|987007443461605171‏
996 ‎‡2  LC|no2016025568‏
996 ‎‡2  DNB|1058725475‏
996 ‎‡2  SUDOC|112255515‏
996 ‎‡2  PLWABN|9810606776505606‏
996 ‎‡2  ISNI|0000000459981325‏
996 ‎‡2  DNB|1192529669‏
996 ‎‡2  NYNYRILM|307360‏
996 ‎‡2  ISNI|0000000476851215‏
996 ‎‡2  SUDOC|103459553‏
996 ‎‡2  NYNYRILM|307367‏
996 ‎‡2  LC|n 78087324‏
996 ‎‡2  SUDOC|201665867‏
996 ‎‡2  LC|n 2014070273‏
996 ‎‡2  CYT|AC000256591‏
996 ‎‡2  DNB|1336257652‏
996 ‎‡2  NUKAT|n 2016156112‏
996 ‎‡2  NYNYRILM|307383‏
996 ‎‡2  NYNYRILM|307382‏
996 ‎‡2  NUKAT|n 2009702249‏
996 ‎‡2  LC|nr 91009214‏
996 ‎‡2  ISNI|0000000054700329‏
996 ‎‡2  RERO|A027144117‏
996 ‎‡2  LC|no2024014631‏
996 ‎‡2  DNB|1152967606‏
996 ‎‡2  ISNI|000000006369846X‏
996 ‎‡2  DNB|171759893‏
996 ‎‡2  PLWABN|9812422790805606‏
996 ‎‡2  NTA|323265391‏
996 ‎‡2  LC|n 86075778‏
996 ‎‡2  ISNI|0000000063379610‏
996 ‎‡2  ISNI|0000000393652827‏
996 ‎‡2  RERO|A027221808‏
996 ‎‡2  LC|n 2021014398‏
996 ‎‡2  DNB|1046614584‏
996 ‎‡2  LC|n 2016034552‏
996 ‎‡2  NII|DA13216636‏
996 ‎‡2  SUDOC|233297804‏
996 ‎‡2  LC|nr 98032359‏
996 ‎‡2  ISNI|0000000443547575‏
996 ‎‡2  J9U|987012161269905171‏
996 ‎‡2  LC|n 2020180189‏
996 ‎‡2  DNB|1268642045‏
996 ‎‡2  CYT|AC000642173‏
996 ‎‡2  ISNI|0000000501407942‏
996 ‎‡2  LC|no2017020068‏
996 ‎‡2  LC|n 90610295‏
996 ‎‡2  DNB|1208303465‏
996 ‎‡2  ISNI|0000000382655029‏
996 ‎‡2  NSK|000714178‏
996 ‎‡2  BNF|16978950‏
996 ‎‡2  CYT|AC000639193‏
996 ‎‡2  BIBSYS|4079898‏
996 ‎‡2  DNB|1034860585‏
996 ‎‡2  LC|nr 93014162‏
996 ‎‡2  DNB|1168615836‏
996 ‎‡2  ISNI|0000000050280937‏
996 ‎‡2  DNB|1027645763‏
996 ‎‡2  LC|n 80020111‏
996 ‎‡2  LC|n 82132154‏
996 ‎‡2  NUKAT|n 2013147599‏
996 ‎‡2  LC|n 2015059984‏
996 ‎‡2  CYT|AC000642126‏
996 ‎‡2  CYT|AC000656403‏
996 ‎‡2  DNB|1135504601‏
996 ‎‡2  ISNI|0000000501719751‏
996 ‎‡2  CYT|AC000642352‏
996 ‎‡2  ISNI|0000000107761329‏
996 ‎‡2  ISNI|000000049554814X‏
996 ‎‡2  LC|no 89012091‏
996 ‎‡2  LC|n 2006089648‏
996 ‎‡2  NII|DA0155127X‏
996 ‎‡2  LC|n 84122656‏
996 ‎‡2  BNF|17079069‏
996 ‎‡2  CYT|AC000000117‏
996 ‎‡2  DNB|123147999‏
996 ‎‡2  BIBSYS|8022351‏
996 ‎‡2  ISNI|0000000063651397‏
996 ‎‡2  LC|nr 91030434‏
996 ‎‡2  CYT|AC000572455‏
996 ‎‡2  ISNI|0000000504933753‏
996 ‎‡2  BNF|12032723‏
996 ‎‡2  DNB|1342453433‏
996 ‎‡2  DNB|135783682‏
996 ‎‡2  ISNI|0000000064321197‏
996 ‎‡2  NTA|071146547‏
996 ‎‡2  DNB|1150665637‏
996 ‎‡2  NTA|308705726‏
996 ‎‡2  LC|n 2007059541‏
996 ‎‡2  LC|n 2016066378‏
996 ‎‡2  LC|nr 92035800‏
996 ‎‡2  LC|no2021146139‏
996 ‎‡2  LC|no2022054196‏
996 ‎‡2  ISNI|0000000116022560‏
996 ‎‡2  LC|nr 96026567‏
996 ‎‡2  DNB|1071878557‏
996 ‎‡2  CYT|AC000642220‏
996 ‎‡2  DNB|119121771X‏
996 ‎‡2  DNB|138069689‏
996 ‎‡2  LC|n 2015007903‏
996 ‎‡2  CYT|AC000637104‏
996 ‎‡2  DNB|1137537302‏
996 ‎‡2  ISNI|0000000033666344‏
996 ‎‡2  NKC|jo20241241195‏
996 ‎‡2  CYT|AC000638738‏
996 ‎‡2  DNB|1233790242‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Jin, Wang‏ ‎‡2  DNB|1166698440‏ ‎‡3  exact name‏
998 ‎‡a  Jin, Wang‏ ‎‡g  Chinese sculptor, born 1962‏ ‎‡2  JPG|500194039‏ ‎‡3  exact name‏
998 ‎‡a  Jin, Wang‏ ‎‡2  BIBSYS|15005562‏ ‎‡3  exact name‏
998 ‎‡a  Jin, Wang‏ ‎‡2  DBC|87097919080943‏ ‎‡3  exact name‏